IONIQ is honored as GHP’s “Most Outstanding Early-Stage Cancer Detection Solutions Provider, 2022”
Salt Lake City, UT, June 3, 2022 – IONIQ Sciences, Inc. (“IONIQ” or the “Company”) is humbled to announce it has been awarded “Most Outstanding Early-Stage Cancer Detection Solutions Provider, 2022” by Global Health Pharma. We are grateful to have our mission to provide early-stage cancer detection continue to be recognized. Through our novel application of bioimpedance technology, we believe that we’re measuring the body’s systemic response to cancer in the earliest and most-treatable stages of the disease. Our ability to detect smaller 4-8mm pulmonary nodules in early cancer stages with greater accuracy than existing diagnostics is what earned us a ‘Breakthrough Device’ designation from the FDA.
About IONIQ Sciences, Inc.
IONIQ Sciences, Inc. is developing an advanced multi-cancer screening technology for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. IONIQ Sciences operates at the confluence of its Electrical Impedance Analytics (EIA) or bioimpedance technology and Artificial Intelligence (AI). IONIQ Science’s first product utilizing its proprietary analytic platform, the IONIQ ProLung Test™ for lung cancer, has been designated a Breakthrough Device by the U.S. FDA. For more information visit: www.IONIQsciences.com
IONIQ Sciences is proud to be a key supporter and member of the newly formed BioHive, a collective representing the life science and healthcare innovation ecosystem. By embracing diversity and collaboration, BioHive has become the fastest-growing life science community in America and their innovations are improving the lives of millions of patients. To learn more, visit: www.biohive.com
IONIQ Sciences, Inc.
350 W. 800 N., Suite 214
Salt Lake City, Utah 84103